Serina Therapeutics Inc (SER)
AMEXHealth CareBiotechnologySnapshot 2026-11-05
$1.65-2.37%
Close 2026-11-05 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · SER
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
“We continued on our strategic plan, completing enrollment and dosing in Cohort 1 of the SER-252 registrational study ahead of our prior guidance,” said Steve Ledger, Chief Executive Officer of Serin…
Stated in 2 of 2 supplied quarters. Management reported: ““We continued on our strategic plan, completing enrollment and dosing in Cohort 1 of the SER-252 registrational study ahead of our prior guidance,” said Steve Ledger, Chief Executive Officer of Serina.” ““These initial observations strengthen our confidence in SER-252 and are consistent with the profile the program was designed to achieve,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
““We continued on our strategic plan, completing enrollment and dosing in Cohort 1 of the SER-252 registrational study ahead of our prior guidance,” said Steve Ledger, Chief Executive Officer of Serin…”
““With our Phase 1b registrational study of SER-252 now underway and a strengthened balance sheet, Serina is entering an important execution phase as we work toward our first clinical data in patients…”
• Closed Private Placement Financing : In March and April 2026, Serina closed the previously announced private placement of common stock, redeemable warrants and pre-funded warrants, resulting in agg…
Stated in 1 of 2 supplied quarters. Management reported: “• Closed Private Placement Financing : In March and April 2026, Serina closed the previously announced private placement of common stock, redeemable warrants and pre-funded warrants, resulting in aggregate gross proceeds of $21.2 million ("March 2026 PIPE").” “Liquidity Information Cash and cash equivalents totaled $23.0 million as of June 30, 2026.”
“• Closed Private Placement Financing : In March and April 2026, Serina closed the previously announced private placement of common stock, redeemable warrants and pre-funded warrants, resulting in agg…”
• Development Partnership with Gannet BioChem: In June 2026, Serina entered into a development partnership with Gannet BioChem to support process development, scale-up and manufacturing activities fo…
Stated in 2 of 2 supplied quarters. Management reported: “• Development Partnership with Gannet BioChem: In June 2026, Serina entered into a development partnership with Gannet BioChem to support process development, scale-up and manufacturing activities for SER-252.” “We believe this approach has the potential to unlock meaningful value across multiple modalities, and we are building a pipeline and partnership strategy to fully leverage the breadth of the platform.””
“• Development Partnership with Gannet BioChem: In June 2026, Serina entered into a development partnership with Gannet BioChem to support process development, scale-up and manufacturing activities fo…”
“We believe this approach has the potential to unlock meaningful value across multiple modalities, and we are building a pipeline and partnership strategy to fully leverage the breadth of the platform…”
Second Quarter Operating Results Operating expenses: Operating expenses for the three months ended June 30, 2026 and 2025 were $6.8 million and $5.7 million, respectively.
Stated in 2 of 2 supplied quarters. Management reported: “Second Quarter Operating Results Operating expenses: Operating expenses for the three months ended June 30, 2026 and 2025 were $6.8 million and $5.7 million, respectively.” “First Quarter Operating Results Operating expenses: Operating expenses for the three months ended March 31, 2026 and 2025 were $6.3 million and $5.9 million, respectively.”
“Second Quarter Operating Results Operating expenses: Operating expenses for the three months ended June 30, 2026 and 2025 were $6.8 million and $5.7 million, respectively.”
“First Quarter Operating Results Operating expenses: Operating expenses for the three months ended March 31, 2026 and 2025 were $6.3 million and $5.9 million, respectively.”
Strengthen Board of Directors with experienced members to support clinical, partnering, and corporate objectives.
Over the trailing year it converted 0.51x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates (low R² over the window).
21 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.